mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
1e-06 |
mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
2e-05 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
3e-05 |
mRNA |
SB-743921 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
8e-05 |
mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0001 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.0002 |
mRNA |
selumetinib:decitabine (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0004 |
mRNA |
YK 4-279 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0004 |
mRNA |
indisulam |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0005 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.0006 |